Chargement en cours...
Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
BACKGROUND: Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib. Increased thioredoxin level has been reported to be associated with ca...
Enregistré dans:
| Publié dans: | J Hematol Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5828316/ https://ncbi.nlm.nih.gov/pubmed/29482577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0575-7 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|